Natasha Emmanuel

@SRouhanifard @SepidehTavakol2 @NUBioE1 @NortheasternCOE @GenomeTDCC Congratulations 🎉

Congratulations to my first student @SepidehTavakol2, for successfully defending her Ph.D. thesis!! I am so proud of you and all of your hard work!! 🥳

@JustinEngel17 Congratulations Justin!!!

Happy to share our review on chromothripsis!

@JustinLathia @emulkearns @CCLRI Congratulations Erin!!

Excited that I was able to present @emulkearns for her promotion seminar to Project Scientist in our department at the @CCLRI

@emulkearns @cg_hubert @CWRU_Biochem @cwru @caseccc Congratulations @cg_hubert 🎉🎉🎉

HUGE congratulations to my husband @cg_hubert for receiving the NOGA for his first R01. Here's to many more! @CWRU_Biochem @cwru @caseccc

@JustinLathia @CCLRI @DJ_Silver_PhD Love this! Congratulations Dan and Chris!

I believe there is truly something special about the @CCLRI - let me give you yet another example: @DJ_Silver_PhD & Chris Hine in our department had a hallway conversation (not the hallway pictured) several years ago about hydrogen sulfide and #GBM

@SRouhanifard @NatureComms @SepidehTavakol2 @CAMcCormick20 @WanunuLab @NUBioE1 Strong work Rouhanifard Lab!!! Big congrats 🎉

First story from our lab 🥳, out in @NatureComms today! Using direct mRNA sequencing to identify and study pseudouridine mods in human cells and find site with high occupancy. Congrats to @SepidehTavakol2 @CAMcCormick20 @WanunuLab from @NUBioE1 nature.com/articles/s4146…

More exciting research from @TangoTxOncology on the use of #USP1 inhibitors for #BRCAmut tumors

If only it was this easy...😂

VRK1 is a Synthetic Lethal Target in VRK2-deficient #Glioblastoma. aacrjournals.org/cancerres/arti… #btsm @CR_AACR

LITESPARK-003: Cabo + Belzu phase II trial in 1L therapy for mRCC. Encouraging activity data for this combination. #ESMO22

Audience applause for this waterfall plot! Neoadjuvant immune checkpoint inhibition should become the soc in locally advanced MMR-deficient colon cancer! #ESMO22

Incredible data presented by @DrSapnaPatel from S1801 in operable melanoma with neoadjuvant vs. adjuvant pembrolizumab at #ESMO22

Excited to share some exciting work on VRK1/2 synthetic lethality in GBM. Led by my close friend and mentor @ninja_scientist over at Tango Therapeutics. Lots more to discover in the DepMap data! aacrjournals.org/cancerres/arti…

@JustinLathia @TangoTxOncology @CR_AACR @emulkearns Thank you @JustinLathia for the excellent collaboration!! We couldn't have done it without you and the Lathia Lab!!

Congrats to Natasha @ninja_scientist from Tango Therapeutics @TangoTxOncology on leading this exciting study in @CR_AACR on Vrk1 in #GBM #BTSM - appreciate the opportunity to contribute to this exciting new synthetic lethality target! @emulkearns aacrjournals.org/cancerres/arti…

@JulieNadel Ugh 🤮

We continue to build a tower on a rotten foundation and are surprised when it collapses on our students...

If you're attending AACR next month and interested in DNA repair in cancer, check out our poster on targeting BRCA1-mutant tumors with USP1 inhibitors. I had the honor of working on this during my time at Tango Therapeutics and I'm excited that it will see the light of day!

Today, Russia started a full-scale war against Ukraine. We believe in our soldiers and we stay strong. We have to postpone our services till Monday, February 28. We hope you take this short-term disruption with understanding.

Google Betty White .,rose petals Will cascade down your screen and "Thank you for being a friend" will play.

Good to see continued declines in cancer mortality and ongoing improved outcomes in lung cancer. We must pay close attention to trends in breast cancer, prostate cancer, and ongoing disparities. Much more work to be done!